KR20110046537A - 콜라겐­매개된 질병을 치료하기 위한 조성물 및 방법 - Google Patents

콜라겐­매개된 질병을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20110046537A
KR20110046537A KR1020117006197A KR20117006197A KR20110046537A KR 20110046537 A KR20110046537 A KR 20110046537A KR 1020117006197 A KR1020117006197 A KR 1020117006197A KR 20117006197 A KR20117006197 A KR 20117006197A KR 20110046537 A KR20110046537 A KR 20110046537A
Authority
KR
South Korea
Prior art keywords
collagenase
drug
fermentation
lane
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117006197A
Other languages
English (en)
Korean (ko)
Inventor
그레고리 엘. 사바티노
벤자민 제이. 주니어 델 티토
필립 제이. 바셋
헤이즐 에이. 타리아
안토니 지. 히치콕
Original Assignee
옥실리엄 인터내셔널 홀딩스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옥실리엄 인터내셔널 홀딩스, 인코포레이티드 filed Critical 옥실리엄 인터내셔널 홀딩스, 인코포레이티드
Publication of KR20110046537A publication Critical patent/KR20110046537A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020117006197A 2006-01-30 2007-01-30 콜라겐­매개된 질병을 치료하기 위한 조성물 및 방법 Ceased KR20110046537A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US76347006P 2006-01-30 2006-01-30
US60/763,470 2006-01-30
US78413506P 2006-03-20 2006-03-20
US60/784,135 2006-03-20
US11/699,302 2007-01-29
US11/699,302 US7811560B2 (en) 2006-01-30 2007-01-29 Compositions and methods for treating collagen-mediated diseases
PCT/US2007/002654 WO2007089851A2 (en) 2006-01-30 2007-01-30 Compositions and methods for treating collagen-mediated diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087021302A Division KR20080093142A (ko) 2006-01-30 2007-01-30 콜라겐­매개된 질병을 치료하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20110046537A true KR20110046537A (ko) 2011-05-04

Family

ID=38328033

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117006197A Ceased KR20110046537A (ko) 2006-01-30 2007-01-30 콜라겐­매개된 질병을 치료하기 위한 조성물 및 방법
KR1020087021302A Ceased KR20080093142A (ko) 2006-01-30 2007-01-30 콜라겐­매개된 질병을 치료하기 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087021302A Ceased KR20080093142A (ko) 2006-01-30 2007-01-30 콜라겐­매개된 질병을 치료하기 위한 조성물 및 방법

Country Status (17)

Country Link
US (16) US7811560B2 (enExample)
EP (6) EP2474321B1 (enExample)
JP (8) JP5309289B2 (enExample)
KR (2) KR20110046537A (enExample)
CN (2) CN101400788B (enExample)
AU (2) AU2007211313C1 (enExample)
BR (1) BRPI0708017A2 (enExample)
CA (1) CA2637262C (enExample)
DK (2) DK2474321T3 (enExample)
ES (3) ES2729941T3 (enExample)
HU (2) HUE044220T2 (enExample)
IL (6) IL291175B2 (enExample)
MX (1) MX2008009756A (enExample)
NZ (2) NZ569882A (enExample)
PT (2) PT1987141T (enExample)
TR (1) TR201903008T4 (enExample)
WO (1) WO2007089851A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11879141B2 (en) 2012-01-12 2024-01-23 Endo Global Ventures Nucleic acid molecules encoding clostridium histolyticum collagenase II and methods of producing the same
US12448615B2 (en) 2017-03-28 2025-10-21 Endo Operations Limited Method of purifying and isolating collagenase

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2130551B1 (en) 2008-06-02 2012-06-06 Roche Diagnostics GmbH Improved purification of collagenases from clostridium histolyticum liquid culture
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
ES2385239B1 (es) 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
WO2012125948A1 (en) 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
MX350145B (es) 2011-07-20 2017-08-28 Mediwound Ltd Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
WO2013059619A1 (en) * 2011-10-21 2013-04-25 Auxilium Pharmaceuticals, Inc. Method of treating or reducing efp
ITPD20120118A1 (it) 2012-04-18 2013-10-19 Fidia Farmaceutici "nuovo processo di produzione e purificazione dell'enzima collagenasi da vibrio alginolyticus"
JP2015521169A (ja) 2012-05-01 2015-07-27 プロテオリース リミテッド 抜歯する方法
BR102012013110A2 (pt) 2012-05-31 2014-05-27 Cristalia Prod Quimicos Farm Meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
EP3834840B8 (en) 2013-03-15 2025-09-17 Endo Biologics Limited Treatment method and product for uterine fibroids using purified collagenase
US20160000890A1 (en) * 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
CA2915814A1 (en) * 2013-06-18 2014-12-24 Imprimis Pharmaceuticals Inc. Local use of pentoxifylline to treat peyronie's disease
US10383875B2 (en) 2013-06-18 2019-08-20 Harrow Ip, Llc Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US10117892B2 (en) * 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105412917B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
DE202014105440U1 (de) * 2014-11-12 2016-02-15 Bilz Werkzeugfabrik Gmbh & Co. Kg Werkzeugaufnahme
KR101723168B1 (ko) 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
US10303245B2 (en) * 2015-05-04 2019-05-28 Adobe Inc. Methods and devices for detecting and responding to changes in eye conditions during presentation of video on electronic devices
KR20230003601A (ko) 2017-03-01 2023-01-06 엔도 벤쳐즈 리미티드 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
JP7628492B2 (ja) 2018-09-18 2025-02-10 エンド グローバル エステティックス リミテッド セルライトを治療するための組成物および方法
MX2021008017A (es) 2019-01-06 2021-08-05 Endo Global Aesthetics Ltd Formulaciones de colagenasa y metodos de produccion de las mismas.
CA3157517A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
WO2023131588A1 (en) 2022-01-05 2023-07-13 Nordmark Pharma Gmbh Culture medium for cultivating hathewaya histolytica (or clostridium histolyticum) and the production of one or more proteases
CN116102638B (zh) * 2023-01-09 2025-05-16 中国农业科学院农产品加工研究所 基于亲和吸附富集骨胶原蛋白成骨活性肽的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61289885A (ja) * 1985-06-14 1986-12-19 Nitta Zerachin Kk コラゲナ−ゼおよびコラゲナ−ゼの製造方法
JP2898022B2 (ja) * 1989-09-05 1999-05-31 株式会社ニッピ コラーゲン分解酵素の製造方法
CA2047306A1 (en) * 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) * 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
CA2138948A1 (en) * 1992-06-22 1994-01-06 Hun-Chi Lin Molecular cloning of the genes responsible for collagenase production from clostridium histolyticum
JP3186881B2 (ja) * 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
CA2189646C (en) * 1994-06-24 1999-05-25 Francis E. Dwulet A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CZ280397A3 (cs) * 1995-03-16 1998-04-15 Knoll Aktiengesellschaft Nové, definované směsi enzymů pro získávání buněk a pro léčbu poranění
US5989888A (en) * 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
ATE272109T1 (de) * 1996-11-19 2004-08-15 Roche Diagnostics Gmbh Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) * 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
CN1308442C (zh) * 2001-07-02 2007-04-04 诺尔玛克药物有限责任及股份两合公司 纯化酶的方法和按此产生出的经纯化的酶以及该酶的用途
EP1462519A1 (en) * 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) * 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
NZ548871A (en) * 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
US7355027B2 (en) * 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
EP1781697B1 (en) * 2004-07-07 2009-04-22 H.Lundbeck A/S Novel carbamylated epo and method for its production
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
ES2548516T3 (es) * 2005-01-21 2015-10-19 The Research Foundation Of The State University Of New York Métodos para el tratamiento de la capsulitis adhesiva
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11879141B2 (en) 2012-01-12 2024-01-23 Endo Global Ventures Nucleic acid molecules encoding clostridium histolyticum collagenase II and methods of producing the same
US11975054B2 (en) 2012-01-12 2024-05-07 Endo Global Ventures Nucleic acid molecules encoding clostridium histolyticum collagenase I and methods of producing the same
US12263209B2 (en) 2012-01-12 2025-04-01 Endo Biologics Limited Pharmaceutical compositions comprising collagenase I and collagenase II
US12448615B2 (en) 2017-03-28 2025-10-21 Endo Operations Limited Method of purifying and isolating collagenase

Also Published As

Publication number Publication date
ES2992881T3 (en) 2024-12-19
AU2012200863A1 (en) 2012-03-08
JP2009525283A (ja) 2009-07-09
EP4483952A2 (en) 2025-01-01
JP2021113212A (ja) 2021-08-05
US20100330065A1 (en) 2010-12-30
EP2474321A1 (en) 2012-07-11
US7811560B2 (en) 2010-10-12
WO2007089851A2 (en) 2007-08-09
DK2474321T3 (da) 2019-06-03
AU2007211313A1 (en) 2007-08-09
AU2007211313B2 (en) 2011-12-01
IL277322A (en) 2020-10-29
AU2007211313C1 (en) 2014-05-22
IL264361A (en) 2019-02-28
CN105999244B (zh) 2022-01-11
EP2474319A1 (en) 2012-07-11
IL291175A (en) 2022-05-01
JP2017006143A (ja) 2017-01-12
ES2709202T3 (es) 2019-04-15
IL264361B (en) 2020-09-30
JP6792596B2 (ja) 2020-11-25
US20210106659A1 (en) 2021-04-15
IL254184B (en) 2019-02-28
JP2015128447A (ja) 2015-07-16
CA2637262C (en) 2014-08-19
EP2474321B1 (en) 2019-04-17
IL291175B1 (en) 2023-10-01
HUE041764T2 (hu) 2019-05-28
EP3508571A1 (en) 2019-07-10
NZ593907A (en) 2013-02-22
MX2008009756A (es) 2008-12-18
US20160000889A1 (en) 2016-01-07
US20110243909A1 (en) 2011-10-06
US20110243919A1 (en) 2011-10-06
US20110243908A1 (en) 2011-10-06
CN101400788B (zh) 2016-06-29
ES2729941T3 (es) 2019-11-07
US20100233151A1 (en) 2010-09-16
KR20080093142A (ko) 2008-10-20
TR201903008T4 (tr) 2019-03-21
JP5309289B2 (ja) 2013-10-09
EP2474320A1 (en) 2012-07-11
NZ569882A (en) 2012-03-30
US20110189153A1 (en) 2011-08-04
HUE044220T2 (hu) 2019-10-28
IL277322B (en) 2022-04-01
US20140004094A1 (en) 2014-01-02
EP1987141A4 (en) 2009-11-18
PT2474321T (pt) 2019-07-25
IL245434A (en) 2017-10-31
JP7191152B2 (ja) 2022-12-16
JP6389493B2 (ja) 2018-09-12
BRPI0708017A2 (pt) 2011-05-17
EP3508571B1 (en) 2024-08-21
JP6851943B2 (ja) 2021-03-31
WO2007089851A3 (en) 2008-01-03
JP2018143258A (ja) 2018-09-20
JP2020039371A (ja) 2020-03-19
PT1987141T (pt) 2019-03-04
JP2017218452A (ja) 2017-12-14
EP1987141B8 (en) 2019-03-06
IL192878A (en) 2013-03-24
EP1987141B1 (en) 2018-12-05
CN101400788A (zh) 2009-04-01
DK1987141T3 (en) 2019-03-25
CA2637262A1 (en) 2007-08-09
JP6944989B2 (ja) 2021-10-06
AU2012200863B2 (en) 2014-08-28
IL192878A0 (en) 2009-02-11
IL254184A0 (en) 2017-10-31
US20110189163A1 (en) 2011-08-04
JP2012070758A (ja) 2012-04-12
CN105999244A (zh) 2016-10-12
EP4483952A3 (en) 2025-04-02
US20240299508A1 (en) 2024-09-12
JP6230200B2 (ja) 2017-11-15
EP1987141A2 (en) 2008-11-05
US20070224183A1 (en) 2007-09-27
US20110243920A1 (en) 2011-10-06
IL291175B2 (en) 2024-02-01
IL245434A0 (en) 2016-06-30
US20170087229A1 (en) 2017-03-30
US20110158972A1 (en) 2011-06-30
US20230158127A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
US20230158127A1 (en) Compositions and methods for treating collagen-mediated diseases
HK40122399A (en) Compositions suitable for treating collagen-mediated diseases
HK1130077A (en) Compositions and methods for treating collagen-mediated diseases
HK40011456B (en) Compositions suitable for treating collagen-mediated diseases
HK1130077B (en) Compositions and methods for treating collagen-mediated diseases

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110317

Application number text: 1020087021302

Filing date: 20080829

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120409

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120409

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140507

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140129

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20160810

Appeal identifier: 2014101002740

Request date: 20140507

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20140519

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140602

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20140507

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140507

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130909

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20120130

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2014101002740; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20140507

Effective date: 20160810

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160810

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20140507

Decision date: 20160810

Appeal identifier: 2014101002740

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2016201007534; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20160810

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20170810

Appeal identifier: 2016201007534

Request date: 20161010

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2016201007534; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20161010

Effective date: 20170810

PJ1302 Judgment (patent court)

Patent event date: 20170818

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20161010

Decision date: 20170810

Appeal identifier: 2016201007534

Appeal kind category: Appeal against decision to decline refusal

PJ2002 Appeal before the supreme court

Comment text: Petition of Appeal before the Supreme Court

Patent event date: 20170825

Patent event code: PJ20022R01D

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event date: 20160810

Patent event code: PJ20021S01I

Request date: 20170825

Appeal identifier: 2017301002086

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20171207

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2017301002086; JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170825

Effective date: 20171207

PJ1303 Judgment (supreme court)

Comment text: Written Judgment (Supreme Court)

Patent event date: 20171207

Patent event code: PJ13031S01D

Decision date: 20171207

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170825

Appeal identifier: 2017301002086